ArticleHeliyon2024
Optimized co-delivery of curcumin and methylprednisolone using polyvinyl alcohol-coated CuO nanoparticles for synergistic rheumatoid arthritis treatment.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoparticle embedded dot matrix transdermal patches: a novel approach for targeted and controlled drug delivery in rheumatoid arthritis.Inflammopharmacology · 2026Review
- Parishin E from ginger-processedFrontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of methylprednisolone (MPDL) and curcumin (CUR) for treating rheumatoid arthritis (RA) offers several therapeutic advantages. This synergy allows for a reduction in the dosage of methylprednisolone, minimizing potential side effects associated with long-term steroid use while maintaining or enhancing the treatment's effectiveness. The objective of this study is to prepare drug carriers for MPDL and CUR aimed at treating RA, utilizing Freund's Complete Adjuvant-induced arthritic rat model (AIA). CuO nanoparticles (NPs) were synthesized using ultrasound by reducing copper (II) sulfte pentahydrate with sodium borohydride in a basic solution. Subsequently, these nanoparticles were incrementally added to a polyvinyl alcohol (PVA) solution to ensure controlled integration of PVA-coated CuO NPs. Field Emission Scanning Electron Microscopy (FE-SEM) analysis revealed that the CuO nanoparticles and PVA-coated CuO NPs averaged sizes of 50.7 nm and 104.8 nm, respectively. Furthermore, the PVA-coated CuO NPs demonstrated remarkable biocompatibility, with cell viability ranging from 88.1 % to 92.1 % at concentrations of 0.1 μg/mL and 50 μg/mL after 72 h, as validated through the MTT assay. The PVA-coated CuO NPs exhibited a more controlled and gradual drug release profile for both CUR and MPDL when compared to the PVA matrix. CUR@MPDL@PVA-coated CuO NPs demonstrated the most substantial reduction in hind paw swelling and the minimal clinical scores among all treatment groups, signaling enhanced anti-inflammatory effects. CUR@MPDL@PVA-coated CuO NPs also notably reduced the concentrations of pro-inflammatory cytokines TNF-α and IL-1β when measured against the AIA rats and the groups treated with free agents. Therefore, CUR@MPDL@PVA-coated CuO nanoparticles can be used in biomedical applications due to their size, biocompatibility, and anti-inflammatory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.